This inventor holds 4 USPTO granted patents and 4 published patent applications. Top assignee: Miragen Therapeutics, Inc.. Active years: 2016-2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Boulder, CO (US) (2016 - 2018)
- Erie, CO (US) (2018 - 2019)
Company Filing History:
Years Active: 2016-2019
Title: Innovations by Corrie Lynn Gallant-Behm: A Focus on miRNA Therapeutics
Introduction: Corrie Lynn Gallant-Behm, an accomplished inventor based in Erie, CO, has made significant contributions to the field of molecular therapeutics. With four patents to his name, his work revolves around the development of targeted treatments that leverage microRNA (miRNA) technology to promote healing and prevent fibrotic conditions.
Latest Patents: Gallant-Behm's latest innovations include patents focusing on miR-92 inhibitors and miR-29 mimics. The patent for "MiR-92 inhibitors and uses thereof" details a novel approach to inhibit the activity of miR-92 through oligonucleotide inhibitors. This invention outlines methods for evaluating the effectiveness of therapeutics aimed at enhancing wound healing by modulating miR-92 function. Additionally, the patent titled "miR-29 mimics and uses thereof" presents synthetic oligonucleotide mimetics of miR-29, which can be utilized in pharmaceutical compositions to treat conditions resulting from the dysregulation of extracellular matrix genes, particularly tissue fibrotic conditions.
Career Highlights: As a key member of Miragen Therapeutics, Inc., Gallant-Behm has played a pivotal role in advancing the company's mission to develop RNA-targeted therapies that address serious medical needs. His expertise in molecular biology and innovative approach have positioned him as a leader in the field of miRNA therapeutics.
Collaborations: Throughout his career, Gallant-Behm has worked alongside talented professionals such as Christina Marie Dalby and Rusty L Montgomery. These collaborations have contributed to the successful development and commercialization of groundbreaking therapeutic solutions.
Conclusion: Corrie Lynn Gallant-Behm's innovative work exemplifies the potential of microRNA therapeutics in addressing critical health issues. His contributions to the field through his patents not only enhance scientific understanding but also pave the way for new treatments that could significantly improve patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile